Neuren Pharmaceuticals Limited
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| NURPF | ACAD | NGNE | 1875.HK | B9A.F | TVTX | |
|---|---|---|---|---|---|---|
| Market cap | 1.81B | 3.70B | 551.91M | 2.56B | 2.45B | 5.03B |
| P/E (TTM) | 142.8 | 9.6 | — | — | 250.7 | — |
| Forward P/E | 49.2 | 23.3 | -4.8 | 42.9 | — | 9.9 |
| Price/book | 7.7 | 3.0 | 2.0 | 3.8 | 1.2 | 222.1 |
| Dividend yield | 1.50% | — | — | — | 0.68% | — |
| 1-year change | +21.72% | −7.88% | +3.45% | +73.06% | +5.23% | +57.42% |
| Today | 0.00% | +4.38% | +3.41% | +5.54% | −0.29% | +6.09% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All NURPF news ›Neuren Pharmaceuticals: Spending More to Grow Beyond DAYBUE
Drug development is a game of patience. Investors are already wondering where the next wave of growth will come from. Published on 10/21/2026 at 05:03 am EDT - Modified on 10/21/2026 at 07:55 am EDT Australia’s newest blueprint for the…
What lies on the calendar for Neuren Pharmaceuticals (ASX:NEU) after its patent boost?
How could gold’s retreat from recent highs affect Evolution Mining? The newly allowed patent covers weight-banded dosing of trofinetide for the treatment of Rett syndrome, which reflects how the medicine is currently prescribed. Neuren…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- kalkinemedia.com1
- marketscreener.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 2 articles, not a forecast.